Our laboratory R&D efforts over the last four years have produced significant intellectual property surrounding our cellular processing platform and bio-materials for which we currently have five U.S. patents pending and one patent issued.The issued patent covers our cutting edge method to formulate and manufacture 11 types of stem cell growth and differentiation mediums used in research and cellular therapy. We are in discussions with research universities to develop a unique pipeline of proprietary products and services that we believe target our proposed long term commercial growth strategy: to create standardized tissue processing, clinical grade tissue samples, stem cell samples and bio-materials for use in research and human applications.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.